RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk
加拿大皇家银行将Beam Therapeutics的目标股价从27美元上调至35美元，原因是 “更有利的监管环境”，保持了行业表现，存在投机风险
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册